tbuckley/cabot-search huggingface dataset:
PATH-44. RACE INFLUENCES PATIENT SURVIVAL IN GLIOMA AND ASSOCIATES WITH GENETIC MARKERS OF RETINOIC ACID METABOLISM
Authors: Meijing Wu, Jason Miska, Peng Zhang, J Robert Kane, Ting Xiao, Irina Balyasnikova, James Chandler, Craig Horbinski, Maciej Lesniak
Journal: Neuro-Oncology (2017)

African Americans (AA) have a significantly decreased incidence of glioma compared to Caucasians. However, it is not known whether the molecular biology of gliomas in AA patients fundamentally differ from those occurring in Caucasians. This study aims to investigate racial differences in clinical outcome and molecular patterns among glioma patients. Clinical information and molecular profiles (including gene expression array, non-silent somatic mutation, DNA methylation and protein expression) were obtained from The Cancer Genome Atlas (TCGA) for both lower-grade glioma (LGG) and glioblastoma (GBM). Electronic clinical information was collected for all glioma patients treated at Northwestern University between 2006 and 2016. For clinical data, LGG and GBM were analyzed together and then separately. Molecular files were examined in GBM patients only. 931 Caucasians and 64 AA glioma patients from TCGA were analyzed. AA with Karnofsky Performance Score (KPS) ≥80 have significantly lower risk of death than similar Caucasian GBM patients (HR [95%CI] = 0.47[0.23, 0.98], P=0.0444, C index=0.68). Therefore, we further compared gene expression profiles between AA GBM patients and Caucasians with KPS≥80. Extrapolation of genes significantly associated with increased AA patient survival revealed a set of 13 genes with a possible role in this association, including elevated expression of genes previously identified as increased in AA breast and colon cancer patients (e.g. CRYBB2). Furthermore, gene set enrichment analysis revealed retinoic acid metabolism as a pathway significantly upregulated in AA GBM patients who survive longer than Caucasians (Z-score=-2.10, Adjusted P-value=0.0449). African Americans have prolonged survival with glioma which is influenced by initial KPS score. Genes previously associated with both racial disparities in cancer, and pathways associated with RA metabolism, may play important roles in AA gliomas. More work is needed to better understand the reasons for racial disparities in glioma frequency and outcomes.
MA 02.03 Selective Histone Deacetylase Inhibitor ACY-241 Plus Nivolumab for Refractory Advanced NSCLC: Results From a Phase 1b Study
Authors: M. Awad, Y. Le Bruchec, R. Markelewicz, P. Chen, A. Fandi, A. Spira
Journal: Journal of Thoracic Oncology (2017)
Programa de Epidemiología Aplicada de Campo
Authors: J. F. Martinez Navarro, D Herrera, Candi Sanchez Barco
Journal: Eurosurveillance (2001)

En el ano 1994 se inicio, en el Instituto de Salud Carlos III, el Programa de Epidemiologia Aplicada de Campo (PEAC), estando encomendada su gestion al Centro Nacional de Epidemiologia, en coordinacion con la Escuela nacional de Sanidad, con el apoyo del Ministerio de Sanidad y Consumo y de las Consejerias de Sanidad de las diferentes Comunidades Autonomas de Espana.
Epidémiologie des infections invasives à méningocoques en France en 2003
Authors: A Perrocheau, M K Taha, D Lévy-Bruhl
Journal: Eurosurveillance (2005)

La surveillance nationale des infections invasives a meningocoques (IIM) est basee sur un systeme de declaration obligatoire. La definition de cas pour la declaration a ete elargie en juillet 2002 afin d’inclure les cas cliniques sans isolement de souche. Le systeme de detection des alertes IIM a ete renforcee en 2003 avec la mise en place d’un systeme de declaration continue et d’une analyse hebdomadaire par departement, par serogroupe et par d’âge. L’evaluation reguliere de l’exhaustivite de de la surveillance, par la methode de capture-recapture, permet de corriger les taux d’incidence en prenant en compte la sous-declaration. 
En 2003, 803 cas ont ete notifies. Apres correction de la sous-declaration, l’incidence estimee etait de 1,78/100 000. Apres l’exclusion des cas cliniques sans isolement de souches (repondants uniquement aux nouveaux criteres) l’augmentation en 2002-2003 etait de 4%. L’incidence diminuait avec l’âge, les valeurs les plus hautes concernant les enfants de moins de un an (20/100 000), les enfants de 1 et 2 ans (11/100 000) et les enfants âges de 17 ans (7/100 000). Le taux de mortalite etait de 12%. Cinquante-neuf pour cent des cas etaient dus au serogroupe B, 32% au serogroupe C, 5% au serogroupe W135. Les 4% restants etaient dus au serogroupe Y et aux infections a meningocoques non serogroupables. Les patients presentant un purpura fulminans ayant recu un antibiotique par voie intraveineuse avant l’hospitalisation presentaient un taux de mortalite plus faible que les patients non traites.
En 2003, 5 situations ont necessite une attention particuliere : deux episodes de cas groupes d’IIM de serogroupe B, une epidemie d’IIM liee a une souche de serogroupe B d’un complexe clonal connu pour son potentiel a generer des epidemiesdans un departement, et deux departements ou le seuil d’alerte des cas d’IIM de serogroupe C a ete atteint et ou des campagnes de vaccination ont ete recommandees.
Twenty-four-hour time course of intraocular pressure in healthy and glaucomatous africans: relation to sleep patterns11Each of the authors discloses any type of financial interest that is related to the manuscript and any type of personal or family ownership and discloses any interest in marketing any product, drug, instrument, or piece of equipment discussed in the manuscript.
Authors: Christian Noël, Abdoua M Kabo, Jean-Paul Romanet, Alain Montmayeur, Alain Buguet
Journal: Ophthalmology (2001)
P1.15-001 Ipilimumab Increases Th1/Th2 and Inflammatory Cytokines Counteracting Chemotherapy Effects in Small Cell Lung Cancer
Authors: M. Hardy-Werbin, P. Rocha, O. Arpí, Á. Taus, D. Joseph-Pietras, A. Rovira, J. Albanell, C. Ottensmeier, E. Arriola
Journal: Journal of Thoracic Oncology (2017)
PDCT-14. CLINICALLY INTEGRATED SEQUENCING SIGNIFICANTLY ALTERS THERAPY IN CHILDREN AND YOUNG ADULTS WITH HIGH-RISK GLIAL BRAIN TUMORS
Authors: Carl Koschmann, Yi-Mi Wu, Chandan Kumar, Robert Lonigro, Pankaj Vats, Katayoon Kasaian, Marcin Cieslik, Xuhong Cao, Kevin Frank, John R Prensner, Andrew Zureick, Jessica Everett, Bailey Anderson, Brendan Mullan, Bernard Marini, Sandra Camelo-Piragua, Sriram Vennneti, Paul Mc Keever, Kathryn A McFadden, Andrew Lieberman, Marcia Leonard, Cormac O Maher, Hugh J L Garton, Karin Muraszko, Patricia Robertson, Dan Robinson, Arul Chinnaiyan, Rajen Mody
Journal: Neuro-Oncology (2017)

Brain tumors have become the leading cause of cancer-related mortality in young patients. The role of routine sequencing in younger patients with brain tumors is not fully established, and it remains unclear which patient patients will benefit most from the integration of germline/tumor sequencing into routine pediatric neuro-oncology care. The goal of this study was to evaluate the feasibility and utility of DNA and RNA sequencing of children and adolescents with high-risk brain tumors, as well as to document the clinical utility of targeted therapies. Fifty-two children and young adults with brain tumors designated by treating neuro-oncologist to be high risk enrolled in a prospective, observational, consecutive case-series, in which participants underwent integrative clinical exome (tumor and germline DNA) and transcriptome (tumor RNA) sequencing and genetic counseling. Results were discussed in a multi-institutional brain tumor precision medicine teleconference using a platform (“CNS TAP”) to score targeted agents by their pre-clinical, clinical and pharmacologic properties in the selection of targeted therapies for brain tumors. Sequencing revealed a potentially actionable germline or tumor alterations in 25 (63%) of 40 tumors with adequate tissue, of which 21 (53%) resulted in an impact on treatment or change of diagnosis. Eight (20%) of sequenced tumors harbored an oncogenic fusion isolated on RNA sequencing. Seventeen of 20 patients (85%) with glial tumors were found to have a potentially actionable result, which resulted in change of therapy in 14 (70%) patients. Six (15%) patients who underwent therapy changes had potential clinical benefit (partial response or stable disease greater than 6 months on therapy). Selection of personalized agents for children and young adults with high risk brain tumors based on integrative clinical sequencing is feasible and resulted in a change in therapy in over two-thirds of children and young adults with high-risk glial tumors.
<i>RASA1</i> and <i>NF1</i> are Preferentially Co-Mutated and Define A Distinct Genetic Subset of Smoking-Associated Non–Small Cell Lung Carcinomas Sensitive to MEK Inhibition
Authors: Takuo Hayashi, Patrice Desmeules, Roger S. Smith, Alexander Drilon, Romel Somwar, Marc Ladanyi
Journal: Clinical Cancer Research (2017)

Abstract Purpose: Ras-GTPase–activating proteins (RasGAP), notably NF1 and RASA1, mediate negative control of the RAS/MAPK pathway. We evaluated clinical and molecular characteristics of non–small cell lung carcinoma (NSCLC) with RASA1 mutations in comparison with NF1-mutated cases. Experimental Design: Large genomic datasets of NSCLC [MSK-IMPACT dataset at MSKCC (n = 2,004), TCGA combined lung cancer dataset (n = 1,144)] were analyzed to define concurrent mutations and clinical features of RASA1-mutated NSCLCs. Functional studies were performed using immortalized human bronchial epithelial cells (HBEC) and NSCLC lines with truncating mutations in RASA1, NF1, or both. Results: Overall, approximately 2% of NSCLCs had RASA1-truncating mutations, and this alteration was statistically, but not completely, mutually exclusive with known activating EGFR (P = 0.02) and KRAS (P = 0.02) mutations. Unexpectedly, RASA1-truncating mutations had a strong tendency to co-occur with NF1-truncating mutations (P &amp;lt; 0.001). Furthermore, all patients (16/16) with concurrent RASA1/NF1-truncating mutations lacked other known lung cancer drivers. Knockdown of RASA1 in HBECs activated signaling downstream of RAS and promoted cell growth. Conversely, restoration of RASA1 expression in RASA1-mutated cells reduced MAPK and PI3K signaling. Although growth of cell lines with inactivation of only one of these two RasGAPs showed moderate and variable sensitivity to inhibitors of MEK or PI3K, cells with concurrent RASA1/NF1 mutations were profoundly more sensitive (IC50: 0.040 μmol/L trametinib). Finally, simultaneous genetic silencing of RASA1 and NF1 sensitized both HBECs and NSCLC cells to MEK inhibition. Conclusions: Cancer genomic and functional data nominate concurrent RASA1/NF1 loss-of-function mutations as a strong mitogenic driver in NSCLC, which may sensitize to trametinib. Clin Cancer Res; 24(6); 1436–47. ©2017 AACR. See related commentary by Kitajima and Barbie, p. 1243
Observations on a 2-Step Approach to Screening for Parkinson Disease—Reply
Authors: Danna Jennings, Andrew Siderowf, Kenneth Marek
Journal: JAMA Neurology (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Neurology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Neurology journal
P1.03-013 Monitoring of ALK Fusions and Mutations in Advanced ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients
Authors: L. Mezquita, J. Remon, C. Nicotra, M. Noerholm, K. Brinkmann, D. Planchard, C. Jovelet, E. Auclin, C. Flinspach, J. Hurley, J. Skog, A. Gazzah, C. Caramella, J. Adam, L. Lacroix, N. Auger, L. Friboulet, J. Soria, B. Besse
Journal: Journal of Thoracic Oncology (2017)
TMIC-22. DECIPHERING GLIOMA INTRINSIC TRANSCRIPTIONAL SUBTYPES IDENTIFIES TUMOR EVOLUTION ASSOCIATES WITH CHANGES IN IMMUNE-MICROENVIRONMENT
Authors: Qianghu Wang, Baoli Hu, Xin Hu, Massimo Squatrito, Lisa Scarpace, Ana C deCarvalho, Sali Lyu, Pengping Li, Yan Li, Floris P Barthel, Hee Jin Cho, Yu-Hsi Lin, Nikuj Satani, Emmanuel Martinez-Ledesma, Siyuan Zheng, Edward Chang, Adriana Olar, Zhengdao Lan, Gaetano Finocchiaro, Joanna J Phillips, Mitchel S Berger, Konrad Gabrusiewicz, Guocan Wang, Eskil Eskilsson, Jian Hu, Tom Mikkelsen, Ronald Depinho, Florian Muller, Amy Heimberger, Erik Sulman, Do-Hyun Nam, Roel Verhaak
Journal: Neuro-Oncology (2017)

Glioblastoma expression subtypes have been previously been associated with genomic abnormalities, treatment response, and differences in tumor microenvironment. We leveraged IDH wild-type glioblastomas, derivative neurospheres, and single cell gene expression profiles to define three tumor-intrinsic transcriptional subtypes designated as proneural, mesenchymal, and classical, a revision of the previously reported TCGA subtypes. Transcriptomic subtype multiplicity correlated with increased intratumoral heterogeneity and the presence of tumor microenvironment. In silico cell sorting identified macrophages/microglia, CD4+ T lymphocytes, and neutrophils in the glioma microenvironment. NF1 deficiency resulted in increased tumor-associated macrophages/microglia infiltration. Comparison of matching primary and recurrent gliomas elucidated treatment-induced phenotypic tumor evolution, including expression subtype switching, in 45% of our cohort as well as associations between microenvironmental components and treatment response. Gene signature-based tumor microenvironment inference revealed a decrease in invading monocytes and a subtype-dependent increase in macrophages/microglia cells upon disease recurrence. Hypermutation at diagnosis or at recurrence was associated with CD8+ T cell enrichment. Frequency of M2 macrophage detection was associated with short-term relapse after radiation therapy. Our study provides a comprehensive transcriptional and cellular landscape of IDH wild-type glioblastoma during treatment modulated tumor evolution. Characterization of the evolving glioblastoma transcriptome and tumor microenvironment aids in designing more effective immunotherapy trials.
Cancer care for migrant patients: the value of a dedicated service
Authors: R. Casolino, A. Inno, P. Cassandrini, M. Cirillo, R. Magarotto, A. Modena, M. Nicodemo, V. Picece, M. Turazza, F. Marchetti, M. Valerio, F. Alongi, E. Barbieri, Z. Bisoffi, G. Carbognin, G. Ruffo, M. Salgarello, G. Zamboni, M. Verzè, D. Brunelli, S. Gori
Journal: Annals of Oncology (2017)
Annals Story Slam - Pay Your Nanny Well
Authors: Heather E. Gantzer
Journal: Annals of Internal Medicine (2017)

Web Exclusives7 November 2017Annals Story Slam - Pay Your Nanny WellFREEHeather E. Gantzer, MDHeather E. Gantzer, MDPark Nicollet Clinic, Minneapolis, Minnesota (H.E.G.)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/W17-0066 SectionsAboutVisual Abstract ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Video. Annals Story Slam - Pay Your Nanny Well "Pay Your Nanny Well," by Dr. Heather E. Gantzer (Duration 5:01)Building on the popular Annals feature “On Being a Doctor,” storytellers share stories about the experience of doctoring on video. Here, Dr. Gantzer relays her story of balancing doctoring and parenting.For more videos from and information on Annals Story Slam, visit go.annals.org/StorySlam. Comments0 CommentsSign In to Submit A Comment Gary Grammens MDUniversity of Minnesota14 November 2017 Excellent advice Nice talk Heather. Good advice for all physicians trying to balance work with child care responsibilities Author, Article, and Disclosure InformationAffiliations: Park Nicollet Clinic, Minneapolis, Minnesota (H.E.G.)Current Author Address: Heather E. Gantzer, MD, Park Nicollet Clinic, 905 West 48th Street, Minneapolis, MN 55419; e-mail, [email protected]com. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 7 November 2017Volume 167, Issue 9Page: SS1 ePublished: 7 November 2017 Issue Published: 7 November 2017 Copyright & PermissionsCopyright © 2017 by American College of Physicians. All Rights Reserved.Loading ...
PS01.14: Diagnostic Yield in Patients Undergoing Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration: A Single Center Experience
Authors: Sunkaru Touray, Rahul N. Sood, Carlos Martinez-Balzano, Jonathan Holdorf, Paulo J. Oliveira, Scott E. Kopec
Journal: Journal of Thoracic Oncology (2016)
Recommending prolonged bedaquiline use for the treatment of highly resistant strains of tuberculosis
Authors: Jennifer Furin, Erica Lessem, Vivian Cox
Journal: European Respiratory Journal (2017)

We read with interest the article by Caminero et al. [1] proposing a standardised approach to treating both pre-extensively drug-resistant tuberculosis (pre-XDR-TB) and extensively drug-resistant tuberculosis (XDR-TB). This proposal is welcome considering the dearth of evidence-based recommendations on the optimal management of highly resistant tuberculosis (TB) [2]. Given the increasing recognition of the prevalence, morbidity and mortality associated with pre-XDR and XDR-TB, as well as the significant improvement in treatment outcomes with the use of novel and repurposed drugs [3], a clear policy for optimal management of these forms of TB is urgently needed. Treatment of XDR-TB by prolonged use of bedaquiline is appropriate for some individuals <http://ow.ly/VmpN30fzReK>
P3.02-080 DNMT3A Defines a Unique Molecular Class of Chinese Non-Small Cell Lung Cancer Patients
Authors: Y. Zhu, W. Wang, C. Xu, W. Zhuang, Z. Song, R. Chen, Y. Guan, X. Yi, Y. Chen, G. Chen, M. Fang, T. Lv, Y. Song
Journal: Journal of Thoracic Oncology (2017)
ACTR-30. QUANTITATIVE ASSESSMENT OF 5-ALA INDUCED FLUORESCENCE OFFERS A PROMISING APPROACH FOR OBJECTIVE INTRAOPERATIVE ESTIMATION OF TISSUE MALIGNANCY IN DIFFUSE INFILTRATING GLIOMAS
Authors: Georg Widhalm, Seunggu J Han, Jonathan Olson, Jonathan Weller, Joanna J Phillips, Susan Chang, David W Roberts, Mitchel S Berger
Journal: Neuro-Oncology (2017)

Intraoperative visualization of diffuse infiltrating gliomas using 5-aminolevulinic acid (5-ALA) induced fluorescence has been widely adopted to optimize resection. However, the current fluorescence technique is interobserver dependent and thus subjective. Recently, spectroscopic handheld probes were developed that allow intraoperative quantitative assessment of the absolute concentration of 5-ALA induced protoporphyrin IX (PpIX) within tumor tissue. The aim of this study is to test the clinical utility of this spectroscopic probe during glioma resection with correlative visualized fluorescence and histopathologic tissue data. Twenty-three patients with a newly diagnosed (n=12) or recurrent (n=11) diffuse infiltrating glioma (WHO grade II-IV) were included in this prospective clinical trial and 5-ALA was administered approximately three hours prior to resection. During surgery, the absolute PpIX concentration was measured by the spectroscopic handheld probe in multiple intratumoral areas (n=70) of different fluorescence levels (no, mild, moderate or intense fluorescence) as visualized by a modified neurosurgical microscope. Tumor diagnosis was established according to the current WHO 2016 classification including the immunohistochemical assessment of the isocitrate dehydrogenase 1 (IDH1) R132H mutational status. Visible fluorescence was observed in all WHO grade III (n=8) and WHO grade IV gliomas (n=12), whereas fluorescence was absent in all WHO grade II gliomas (n=3). The maximum intratumoral PpIX concentration of each glioma significantly correlated with the WHO tumor grade (k=0.716; p <0.001) and IDH1 mutational status (k=0.446; p=0.033) with lower PpIX concentrations in IDH1 mutant tumors. Furthermore, the PpIX concentrations of different intratumoral regions showed a strong correlation with the visible 5-ALA fluorescence grades (k=0,792; p <0.001). Our data indicate that quantitative assessment of 5-ALA induced fluorescence is a promising approach for immediate and objective intraoperative estimation of tissue malignancy in gliomas. Consequently, these spectroscopic probes will further aid in optimizing the safety and efficacy of surgery for diffuse infiltrating gliomas.
RARE-34. AN INSTITUTIONAL REVIEW OF NINE CASES OF SPINAL HEMANGIOPERICYTOMA
Authors: Pankaj Singh, Raghav Singla, P S Chandra, S S Kale, A K Mahapatra
Journal: Neuro-Oncology (2017)

Spinal hemangiopericytoma are very rare tumors. There are few case reports and occasional case series on them. We have treated nine patients with spinal hemangiopericytoma in last 11 years. We present a retrospective review of our patients with a focus on clinical presentation, radiological features, management, pathology and outcome. Between 2004 and 2016, nine patients were treated for spinal hemangiopericytoma. Histopathological data were reviewed in all cases and clinical and follow-up details were collected from data available in our department. There were 5 males and 4 females, including 2 pediatric patients. Mean age of the patients was 31.1 years. Five patients had dorsal spine involvement and 3 patients had involvement of cervical spine. There was one patient with lumbar spine involvement. Most common location of the tumor was intradural extramedullary. All of them presented with motor weakness. Gross total resection of the tumor was done in 6 patients. Eight patients received postoperative radiotherapy. Histopathology showed anaplastic tumor in 6 cases with high MIB-1 LI. Most of them were positive for CD34, mic-2 and bcl-2. All six patients who underwent gross total resection improved significantly and were self ambulatory in the follow-up period. Two patients who underwent subtotal resection expired due to spread of their disease. Spinal hemangiopericytoma is a very rare tumor. We present a series of cases treated at out institute for the same. Gross total resection is the goal and radiotherapy should be given in case of residual tumor or high grade tumors. Prognosis is good after gross total excision and functional recovery can be expected in most patients.
P1.01-003 Patients Harboring a Novel PIK3CA Point Mutation after Acquired Resistance to Crizotinib in ROS1 Rearrangement Adenocarcinoma: A Case Report
Authors: M. Fang, W. Wang, C. Xu, R. Liu, X. Liao, Y. Zhu, K. Du, W. Zhuang, Y. Chen, G. Chen
Journal: Journal of Thoracic Oncology (2017)